Search Results - dc5axx

9 Results

Sort By:

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct

CDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal...

Published: 7/25/2024 | Inventor(s): Sherry Owen, Renu Lal

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructs, DB4AXX, DB4XXX, DBXXXX, DC1XXX, DC5AXX, DC5XXX, DCXXXX, HIV-1, Immunogenic, Methods, Multi-clade, MULTIVALENT, OID-NCHHSTP-DHPSE, Their

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Therapeutics

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER)...

Published: 7/25/2024 | Inventor(s): John Mascola, Leo Laub, Jinghe Huang, Peter Kwong, Gilad Ofek, Jiang Zhu, Gary Nabel, Ivelin Georgiev, Yongping Yang, Rebecca Rudicell, Mark Connors

Keywords(s): antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, Application > Vaccines

Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag

HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified...

Published: 7/25/2024 | Inventor(s): Gary Nabel

Keywords(s): Against, Cell, chimeric, DC5AXX, DC5XXX, DCXXXX, Development, Duke DNA Project, DXXXXX, Filovirus, GAG, HIV, HIV/SIV, Infection, Optimize, PREVENTIVE, primate, proteins, Responses, T, Vaccine, Vaccine-Induced

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes

Since the onset of the AIDS epidemic more than two decades ago, enormous efforts have been directed to making a vaccine that will protect against human immunodeficiency virus-1 (HIV); an effective vaccine is thought to require the induction of cellular and humoral responses. Vaccine candidates have included a variety of HIV immunogens delivered as...

Published: 7/25/2024 | Inventor(s): Patricia Earl, Linda Wyatt, Bernard Moss

Keywords(s): Alteration, Alternation, BETWEEN, Clinical, CODON, Constructs, DC5AXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Enhanced, ESSENTIAL, Foreign, Gene, Genebetween, GENES, Hyper IgM syndrome, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Insertion, Inserts, Mechanism, MVA/HIV1, PLASMID, recombinant, Severe combined immunodeficiency, x-linked, SHUTTLE, STABILITY, TWO, Vaccine, vaccinia, virus, Wiskott Aldrich syndrome

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Vaccines

Novel System for HIV-1 Vaccine Development

The available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies...

Published: 7/25/2024 | Inventor(s): Peter Kwong

Keywords(s): Against, ANTIGENIC, Anti-HIV-1, ATOMIC, Biotechnology, Broadly, CONFORMATIONALLY, Cryptic, DC5AXX, DC5XXX, DCXXXX, DEFINITION, Details, DXXXXX, Ectodomain, ELICIT, Envelope, Epitope, Epitopes, Epitope-transplant, FUNCTION, Gp120:, gp41, HIV, HIV-1, Immunization, IMMUNOGENS, Level, Membrane-Proximal, Neutralizing, Patent Category - Biotechnology, Reveal, Scaffolds, Stabilized, Strategies, structure, Their, Triggering, V3-Loop, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development

The current technology relates to the construction, characterization and immunogenicity of modified vaccinia Ankara (MVA) recombinant viruses. The MVA double recombinant viruses express modified/truncated HIV-1 Env and mutated HIV Gag Pol under the control of vaccinia virus early/late promoters. This technology describes the MVA double recombinant...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Bernard Moss

Keywords(s): 47 XYY syndrome, DC5AXX, DCXXXX, Double Y, DXXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Monoclonal Antibodies to HIV-1 Vpr

Available for licensing are monoclonal antibodies against HIV-1 viral protein R (Vpr) and the respective hybridoma cell lines expressing the same. The antibodies provide a means for detecting HIV-1 Vpr. Currently, the mechanism of HIV pathogenesis believed to involve viral replication inside immune cells and other cells. At present, there are no...

Published: 7/25/2024 | Inventor(s): Ulrich Schubert, Terrence Phillips, Jonathan (Jon) Yewdell, Jeffrey Kopp

Keywords(s): (4)r syndrome, Abdominal obesity metabolic syndrome, AC6XXX, ACCESSORY, ACXXXX, Antibody-based, AXXXXX, Biological, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, DA4AXX, DA4XXX, DAXXXX, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DDXXXX, Detection, DXXXXX, G syndrome, HIV-1, Hypertelorism with esophageal abnormality and hypospadias, Metabolic syndrome X, Methodologies, monoclonal, N syndrome, Protein, QUANTIFICATION, R(6) syndrome, R(7) syndrome, SAMPLES, Syndrome X, VPR, W syndrome, W syndrome; Syndrome W

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Diagnostics

MVA Expressing Modified HIV envelope, gag, and pol Genes

This invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Patricia Earl, Bernard Moss

Keywords(s): (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, Altered, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, D, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, Envelope, Expressing, G syndrome, GAG, GENES, HAD deficiency, HIS deficiency, Histidinemia, HIV, Hyper IgM syndrome, Hypertelorism with esophageal abnormality and hypospadias, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, MVA, N syndrome, polymerase, R(6) syndrome, R(7) syndrome, Severe combined immunodeficiency, x-linked, Subtype, Syndrome X, W syndrome, W syndrome; Syndrome W, Wiskott Aldrich syndrome

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines